Skip to main content
Top
Published in: Pathology & Oncology Research 4/2018

01-10-2018 | Correction

Correction to: Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment

Authors: Lucheng Zhu, Shirong Zhang, Yanping Xun, Yanping Jiang, Bing Xia, Xueqin Chen, Limin Wang, Hong Jiang, Shenglin Ma

Published in: Pathology & Oncology Research | Issue 4/2018

Login to get access

Excerpt

Correction to: Pathology & Oncology Research
Metadata
Title
Correction to: Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment
Authors
Lucheng Zhu
Shirong Zhang
Yanping Xun
Yanping Jiang
Bing Xia
Xueqin Chen
Limin Wang
Hong Jiang
Shenglin Ma
Publication date
01-10-2018
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 4/2018
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-0421-9

Other articles of this Issue 4/2018

Pathology & Oncology Research 4/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine